Predict your next investment

Asset/Investment Management
arrowmarkpartners.com

See what CB Insights has to offer

Investments

57

Portfolio Exits

28

About ArrowMark Partners

ArrowMark Partners is an SEC-registered investment adviser. The company's investment objective is clear: deliver consistent, asymmetric, non-correlated, risk-adjusted returns by applying fundamental research across the capital structure.

ArrowMark Partners Headquarter Location

100 Fillmore Street Suite 325

Denver, Colorado, 80206,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ArrowMark Partners

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find ArrowMark Partners in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest ArrowMark Partners News

Worldwide Gene Editing Beyond CRISPR Industry to 2035 - Featuring Amgen Ventures, ArrowMark Partners and Baxter Ventures Among Others - ResearchAndMarkets.com

Mar 21, 2022

Isolation of the first site-specific restriction enzyme, Hind II, in the 1970s, became one of the breakthrough advances in biotechnology. This led to the discovery of various methods for manipulating living creatures at the genomic level, thereby, opening up a slew of new possibilities in basic and applied life sciences domain. Soon after, in the 1980s, the US FDA authorized human insulin, marketed under the brand name HUMULIN, as the world's first genetically modified medication. With the development of various DNA modulation technologies, such as zinc-finger nucleases (ZFNs), TAL effector nucleases (TALENs), engineered endonucleases / meganucleases (EMNs) and clustered regularly interspaced short palindromic repeats (CRISPR), genetic engineering and genome editing concepts have gained significant attention over the last two decades. In fact, there have been several advancements in the field of genome editing, which provide investigators the ability to introduce sequence-specific modifications into the genomes of a broad spectrum of cell types and organisms. Several medical researchers and industry stakeholders are presently engaged in exploring the potential of different gene editing technologies for basic research and development of gene editing solutions. However, the therapeutic use of these versatile genetic manipulation tools is only being investigated by selective stakeholders in the pharmaceutical and biotechnology sector. This can be attributed to the implementation of surrogate licensing model, which has granted exclusive control of the associated intellectual property (IP) to the drug developers. Clinical trials of ZFNs, TALENs and meganuclease based therapeutics are primarily focused on infectious diseases and oncological disorders; however, several product candidates against certain hematological disorders, genetic disorders and neurological disorders are being evaluated in discovery and preclinical stages of development. Over time, a number of industry and non-industry players have also been validating the therapeutic applications of these technologies, which has, in turn, prompted the establishment of strategic partnerships. In fact, the growing popularity of such technologies has attracted an investment worth USD 2 billion into companies engaged in this field of research. Promising clinical results, and ongoing technical developments, coupled with the growing interest of biopharmaceutical developers, are anticipated to push the pipeline products to higher phases of development. We believe that the market is likely to evolve at a sustained pace over the next decade. Key Questions Answered Which are the key drugs being developed across early and late stages of development? Which companies are actively involved in conducting clinical trials for ZFNs, TALENs and meganucleases based therapies? What is the focus of various publications related to ZFNs, TALENs and meganucleases based therapies? Which are the leading administering institute centers supporting the research related to gene editing market beyond CRISPR? What kind of partnership models are commonly adopted by industry stakeholders? What is the trend of capital investments in the gene editing beyond CRISPR market? How has the intellectual property landscape in this market evolved over the years? How is the current and future opportunity, related to ZFNs, TALENs and meganucleases based therapies, likely to be distributed across key market segments? Key Topics Covered:

ArrowMark Partners Investments

57 Investments

ArrowMark Partners has made 57 investments. Their latest investment was in Beta Bionics as part of their Series C on February 2, 2022.

CBI Logo

ArrowMark Partners Investments Activity

investments chart

ArrowMark Partners Portfolio Exits

28 Portfolio Exits

ArrowMark Partners has 28 portfolio exits. Their latest portfolio exit was Convene on April 12, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/12/2022

Corporate Majority

$99M

3

12/21/2021

Acquired

$99M

10

10/29/2021

IPO

$99M

4

8/6/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

7/22/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/12/2022

12/21/2021

10/29/2021

8/6/2021

7/22/2021

Exit

Corporate Majority

Acquired

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

10

4

10

10

ArrowMark Partners Acquisitions

2 Acquisitions

ArrowMark Partners acquired 2 companies. Their latest acquisition was StoneCastle Cash Management - Bank Investment Platform on February 13, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/13/2020

$99M

Acquired Unit

1

12/9/2019

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/13/2020

12/9/2019

Investment Stage

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

Note

Acquired Unit

Subscribe to see more

Sources

1

10

ArrowMark Partners Team

3 Team Members

ArrowMark Partners has 3 team members, including current Founding Partner, Minyoung Sohn.

Name

Work History

Title

Status

Minyoung Sohn

Founding Partner

Current

Mike Brower

Controller

Former

Vipul Shah

Managing Director

Former

Name

Minyoung Sohn

Mike Brower

Vipul Shah

Work History

Title

Founding Partner

Controller

Managing Director

Status

Current

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.